{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:40:57Z","timestamp":1787064057841,"version":"build-2736575974"},"reference-count":28,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2011,3,1]],"date-time":"2011-03-01T00:00:00Z","timestamp":1298937600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2011,3]]},"DOI":"10.1016\/j.ijrobp.2009.12.030","type":"journal-article","created":{"date-parts":[[2010,5,26]],"date-time":"2010-05-26T04:54:22Z","timestamp":1274849662000},"page":"1124-1130","source":"Crossref","is-referenced-by-count":20,"title":["External Beam Radiotherapy Followed by 90Y Ibritumomab Tiuxetan in Relapsed or Refractory Bulky Follicular Lymphoma"],"prefix":"10.1016","volume":"79","author":[{"given":"Michael J.","family":"Burdick","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald","family":"Neumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brad","family":"Pohlman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandana A.","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul D.","family":"Tendulkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Macklis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2009.12.030_bib1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0360-3016(00)00780-X","article-title":"Long-term follow-up of patients with Stage III follicular lymphoma treated with primary radiotherapy at Stanford University","volume":"49","author":"Murtha","year":"2001","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2009.12.030_bib2","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/S0360-3016(01)01747-3","article-title":"Long-term results with radiotherapy for Stage I-II follicular lymphomas","volume":"51","author":"Wilder","year":"2001","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2009.12.030_bib3","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/j.ijrobp.2005.08.010","article-title":"Long-term outcome and mortality trends in early-stage, Grade 1-2 follicular lymphoma treated with radiation therapy","volume":"64","author":"Guadagnolo","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2009.12.030_bib4","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1200\/JCO.1996.14.4.1282","article-title":"Is radiotherapy curative for Stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University","volume":"14","author":"Mac Manus","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2009.12.030_bib5","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1182\/blood.V91.5.1644","article-title":"Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies","volume":"91","author":"Shan","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.ijrobp.2009.12.030_bib6","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1182\/blood.V83.2.435.435","article-title":"Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20","volume":"83","author":"Reff","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.ijrobp.2009.12.030_bib7","doi-asserted-by":"crossref","first-page":"3262","DOI":"10.1200\/JCO.2002.11.017","article-title":"Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma","volume":"20","author":"Witzig","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2009.12.030_bib8","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/j.1349-7006.2008.00999.x","article-title":"Japanese Phase II study of 90Y-ibritumomab tiuxetan in patients with relapsed or refractory indolent B-cell lymphoma","volume":"100","author":"Tobinai","year":"2009","journal-title":"Cancer Sci"},{"key":"10.1016\/j.ijrobp.2009.12.030_bib9","doi-asserted-by":"crossref","first-page":"3793","DOI":"10.1200\/JCO.1999.17.12.3793","article-title":"Phase I\/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma","volume":"17","author":"Witzig","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2009.12.030_bib10","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1200\/JCO.2002.11.076","article-title":"Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma","volume":"20","author":"Witzig","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2009.12.030_bib11","doi-asserted-by":"crossref","first-page":"4336","DOI":"10.1182\/blood.V99.12.4336","article-title":"Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: A Phase II multicenter trial","volume":"99","author":"Wiseman","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.ijrobp.2009.12.030_bib12","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1002\/cncr.22617","article-title":"Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan","volume":"109","author":"Witzig","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.ijrobp.2009.12.030_bib13","doi-asserted-by":"crossref","first-page":"7565","DOI":"10.1200\/JCO.2004.00.9217","article-title":"Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas","volume":"23","author":"Fisher","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2009.12.030_bib14","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.ijrobp.2005.01.017","article-title":"Gamma camera scans and pretreatment tumor volumes as predictors of response and progression after Y-90 anti-CD20 radioimmunotherapy","volume":"63","author":"Gokhale","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2009.12.030_bib15","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/cncr.21998","article-title":"Safety and efficacy of external beam radiation therapy for non-Hodgkin lymphoma in patients with prior 90Y-ibritumomab tiuxetan radioimmunotherapy","volume":"107","author":"Justice","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.ijrobp.2009.12.030_bib16","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","article-title":"Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group","volume":"17","author":"Cheson","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2009.12.030_bib17","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2009.12.030_bib18","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1148\/radiol.2463060588","article-title":"B-cell non-Hodgkin lymphoma: PET\/CT evaluation after 90Y-ibritumomab tiuxetan radioimmunotherapy\u2014initial experience","volume":"246","author":"Ulaner","year":"2008","journal-title":"Radiology"},{"key":"10.1016\/j.ijrobp.2009.12.030_bib19","doi-asserted-by":"crossref","first-page":"7088","DOI":"10.1158\/1078-0432.CCR-08-0529","article-title":"Phase II trial of short-course CHOP-R followed by 90Y-ibritumomab tiuxetan and extended rituximab in previously untreated follicular lymphoma","volume":"14","author":"Jacobs","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ijrobp.2009.12.030_bib20","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1034\/j.1600-0609.2002.01542.x","article-title":"Combined therapy in advanced Stages (III and IV) of follicular lymphoma increases the possibility of cure: Results of a large controlled clinical trial","volume":"68","author":"Aviles","year":"2002","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.ijrobp.2009.12.030_bib21","series-title":"Radiobiology for the radiologist","author":"Hall","year":"2006"},{"key":"10.1016\/j.ijrobp.2009.12.030_bib22","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1200\/JCO.2003.07.113","article-title":"Treatment-related myelodysplasia and acute leukemia in non-Hodgkin's lymphoma patients","volume":"21","author":"Armitage","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2009.12.030_bib23","first-page":"229","article-title":"Update on the rational use of tositumomab and iodine-131 tositumomab radioimmunotherapy for the treatment of non-Hodgkin's lymphoma","volume":"2","author":"Burdick","year":"2009","journal-title":"Oncotargets Ther"},{"key":"10.1016\/j.ijrobp.2009.12.030_bib24","first-page":"199","article-title":"Update on the rational use of (90)Y-ibritumomab tiuxetan in the treatment of follicular lymphoma","volume":"2","author":"Lehnert","year":"2009","journal-title":"Oncotargets Ther"},{"key":"10.1016\/j.ijrobp.2009.12.030_bib25","doi-asserted-by":"crossref","first-page":"223","DOI":"10.3816\/CLM.2009.n.044","article-title":"Rituximab plus short-duration chemotherapy followed by yttrium-90 ibritumomab tiuxetan as first-line treatment for patients with follicular non-Hodgkin lymphoma: a Phase II trial of the Sarah Cannon Oncology Research Constortium","volume":"9","author":"Hainsworth","year":"2009","journal-title":"Clin Lymphoma Myeloma"},{"key":"10.1016\/j.ijrobp.2009.12.030_bib26","doi-asserted-by":"crossref","first-page":"5156","DOI":"10.1200\/JCO.2008.17.2015","article-title":"Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma","volume":"26","author":"Morschhauser","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2009.12.030_bib27","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/S1470-2045(08)70039-1","article-title":"Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: A Phase II non-randomised trial (FLUMIZ)","volume":"9","author":"Zinzani","year":"2008","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2009.12.030_bib28","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1093\/annonc\/mdh406","article-title":"Predictive value of Follicular Lymphoma International Prognostic Index (FLIPI) in patients with follicular lymphoma at first progression","volume":"15","author":"Montoto","year":"2004","journal-title":"Ann Oncol"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301609036955?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301609036955?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,6,4]],"date-time":"2020-06-04T21:55:32Z","timestamp":1591307732000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301609036955"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,3]]}},"alternative-id":["S0360301609036955"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2009.12.030","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2011,3]]}}}